Mr. Arun Menawat reports

PROFOUND SURPASSES 2025 TULSA-PRO INSTALLED BASE GOAL

Profound Medical Corp.'s Tulsa-Pro system installed base stood at 78 as of Dec. 31, 2025 -- higher than its previously announced goal of 75 installs by the end of 2025. Profound's Tulsa-Pro qualified sales pipeline also grew to 97 new systems being classified within one of the verify, negotiate and contracting stages at year-end.

"As the installed base grows, we expect that it will lead to higher patient treatment rates and, correspondingly, continued growth of our high-margin recurring revenue," said Profound's chief executive officer and chairman, Arun Menawat. "That is being driven primarily by the Tulsa procedure's ability to treat an unrivaled range of prostate diseases, severities and aggressions while preserving crucial functions like continence and sexual health of the patient. We look forward to releasing our fourth quarter and full-year 2025 financial results near the end of February, 2026."

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets artificial-intelligence-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing Tulsa-Pro, a technology that combines real-time MRI, AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The Tulsa procedure, performed using the Tulsa-Pro system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum, ranging from low-, intermediate- or high-risk prostate cancer to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia to men with BPH only and also to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The Tulsa procedure employs real-time MR guidance for precision to preserve patients' urinary continence and sexual function while killing the targeted prostate tissue through precise sound absorption technology that gently heats it to 55 to 57 C. The Tulsa procedure is an incision- and radiation-free one-and-done procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively and efficiently treated with the Tulsa procedure. There is no bleeding associated with the procedure, no hospital stay is required and most Tulsa patients report quick recovery to their normal routine. Tulsa-Pro is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration. Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumours and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a humanitarian device exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

We seek Safe Harbor.